Legislation roundup: Data security, pharma antitrust and insurance investment in REITs
November 19, 2021 | BY
Susan MokData processors may not take biometric features as the sole method of authenticating individuals' identities. Anti-monopoly guidelines are set forth regarding the active pharmaceutical ingredient sector. Insurance capital may invest in REITs.
Cybersecurity
This premium content is reserved for
China Law & Practice Subscribers.
A Premium Subscription Provides:
- A database of over 3,000 essential documents including key PRC legislation translated into English
- A choice of newsletters to alert you to changes affecting your business including sector specific updates
- Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
Already a subscriber? Log In Now
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]